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Zmazeki F, Tada M,  et al. Resolution of acute hepatitis 
C after therapy with natural beta interferon. Lancet 
1991;338:914-915. 
ABSTRACT 
To test whether interferon can prevent acute non-A, 
non-B hepatitis from becoming chronic, a prospective 
controlled trial was conducted in 26 patients; 11 were 
treated for an average of 30 days with a mean of 52 
megaunits of interferon and 14 acted as controls. 4 
patients in the treatment group who continued to have 
raised serum aminotransferase concentrations after a 
year’s follow-up were given a second course of inter- 
feron. Follow-up at 3 years has revealed that all but 1 
of those treated showed normal serum aminotrans- 
feraae, whereas only 3 controls showed such change 
(p < 0.02). Serum hepatitis C virus RNA became unde- 
tectable in 10 of 11 treated and in only 1 of 12 control 
patients, which suggests that interferon prevents the 
progression of acute non-A, non-B hepatitis to chro- 
nicity by eradicating HCV. 
COMMENTS 
This is an intriguing publication that raises the 
possibility of preventing the development of chronic 
hepatitis C by treating patients with interferon during 
the acute phase of their disease. Although the difference 
between the response rate in the treated group vs. the 
control group, defined either by normalization of serum 
ALT or serum HCV RNA negativity, was statistically 
significant, several issues need to be resolved before the 
interferon treatment of acute hepatitis can become 
accepted. 
Interferon+ treatment was able to clear serum HCV 
RNA and normalize serum aminotransferases in 10 of 
11 treated patients (91%) by the second and third year 
of observation. This is in contrast with results obtained 
among patients with chronic hepatitis C in whom the 
long-term sustained response rate is about 25% (1, 2). 
However, several prospective studies of the natural 
history of non-A, non-B hepatitis have shown that about 
50% of the patients will spontaneously normalize serum 
aminotransferases and probably with disease resolution 
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(3). The higher prevalence of chronic viral infection and 
ALT elevation observed in their control group (8 of 9 and 
8 of 11, respectively) is at variance with the expected rate 
of chronicity (about 50%). Therefore their results might 
be less spectacular than they seem. We lack a readily 
available test for the diagnosis of acute hepatitis C. The 
direct detection of serum HCV RNA by reverse tran- 
scription/polymerase chain reaction is not amenable for 
implementation as a routine assay, and current immu- 
noassays do not allow the diagnosis of the acute phase of 
HCV infection (4). Therefore this potential treatment 
would have to be implemented with the presumptive 
diagnosis of acute hepatitis C; however, this is plagued 
with inaccuracies, and the danger will be to treat 
patients with other causes and subject them to poten- 
tially serious side effects, particularly if their condition 
is an autoimmune liver disease (5, 6). 
The authors have put together patients with a history 
of blood transfusion and others with sporadic type who 
may have a more benign outcome (2). They have not 
provided much information on the underlying condi- 
tions that led to blood transfusions and the degree of 
certainty regarding the diagnosis of “acute” hepatitis C 
in each patient. 
It is unclear to us why the authors chose interferon-@, 
which needs to be administered intravenously, and not 
interferon-a, which can be given subcutaneously and has 
been better studied regarding its efficacy and safety (1, 
2). These results will need to be confirmed with 
interferon-a and in a larger group of patients. 
The mechanisms of chronicity in HCV infection 
remain undefined. In contrast to chronic hepatitis B 
(71, no evidence exists for HCV integration in the host 
genome. Also, HCV does not seem to modify the host 
immune response. Therefore it is unclear how inter- 
feron therapy would be more efficacious in the earlier 
stages of HCV infection as proposed by Omata et al. 
If these observations are confirmed in a larger group 
of patients, the definition of the mechanisms for a more 
effective therapeutic action of interferon in the acute 
phase may give us some insight into what determines 
chronicity in HCV infection. 
The authors were cautious in not recommending the 
use of interferon-@ for acute hepatitis C and we share 
that caution. 
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THE IMMUNE RESPONSE IN CHRONIC HEPATITIS 
B VIRUS INFECTION: THE “CORE” OF 
THE PROBLEM? 
Ehata T, Omata M, Yokosuka 0, Hosoda K, Ohto M .  
Variations in Codons 84-101 in the Core Nucleotide 
Sequence Correlate with Hepatocellular Injury in 
Chronic Hepatitis B Virus Infection. J Clin Invest 
1992;89:332-338. 
ABSTRACT 
Individuals with chronic hepatitis B virus (HBV) 
infection are generally divided into asymptomatic 
healthy carriers and patients with chronic liver 
disease. Several studies have suggested that the hepa- 
titis B core antigen could be an immunological target 
of cytotoxic T lymphocytes (CTL). To investigate the 
possible pressure site from CTL, the entire core region 
of HBV DNA was sequenced in 30 subjects (10 asymp- 
tomatic healthy carriers and 20 patients with chronic 
liver disease). No significant changes in the nucleotide 
sequence and deduced amino acid residue were noted 
in the 10 healthy carriers. In contrast, a cluster of 
changes in a small segment of 18 amino acids (codons 
84-101 from the start of the core gene) was found in 15 
of the 20 chronic liver disease patients. All these 15 
patients had advanced liver diseases (chronic active 
hepatitis and cirrhosis), whereas only mild liver 
disease (chronic persistent hepatitis) was found in the 
five patients without mutations. These data suggest 
that the region with mutation clustering is the major 
target of CTL, and that the mutations evolve under the 
pressure of immune selection. 
COMMENTS 
Of the many patients infected with HBV, only approx- 
imately 10% progress to have chronic liver disease (1). 
Although the clinical and pathological stages in this 
progression are well documented, the mechanisms un- 
derlying the hepatocellular damage remain an enigma. 
These patients have evidence of chronic viral replication, 
as manifested by the presence of HBV DNA and HBeAg. 
However, the hepatic injury is not thought to be related 
to direct viral damage because HBV has not been 
demonstrated to be cytopathic. Instead, most attempts 
to explain the pathogenesis of the chronic liver disease 
have focused on host-related factors. 
The immune response to HBV infection is often 
implicated in the development of liver disease, and the 
hepatic injury is thought to result from the cellular 
immune response to infected hepatocytes (2). To under- 
stand the basis of this hypothesis, one must understand 
the mechanisms of immune recognition involved in 
cellular cytotoxicity. In response to viral infections, the 
immune system generates viral antigen-specific cyto- 
toxic T cells (3). The antigen receptor complex on these 
CD8 lymphocytes recognizes viral antigens as peptides 
bound to class I histocompatibility antigens on the 
surface of infected cells. The peptides are generated by 
digestion of viral antigens and can be as short as 12 to 
14 amino acids in length. Once the antigen receptors 
identify the peptide/class I complex, the T cells bind to 
the virus-infected cells. This binding is stabilized 
through the interaction of adhesion molecules. The T 
cells then lyse the virus-infected target cell (4). This 
action is essential in clearing a viral infection because of 
the need of destroying the intracellular source of viral 
replication. Released virus particles can then be neu- 
tralized and cleared by the circulating antibody. Thus 
hepatocytes are sacrificed by the immune system to 
control HBV. 
Several types of data support the central role that 
antiviral cytotoxic immune responses play in the normal 
immune clearance of HBV infection. Cellular immunity 
to HBcAg is seen in patients who clear the viral infection 
and become antigen negative (5). In contrast, the 
reactivation of viral replication is often seen in patients 
who are immunosuppressed or given immunosup- 
pressive medications (1). Evolution of chronic hepatitis 
B viremia to a nonreplicative, asymptomatic carrier 
state is often accompanied by the development of 
immunity to HBeAg (5 ) .  Importantly, whereas therapy 
with interferon may be effective in inhibiting HBV 
replication, it also augments antiviral cytotoxic immune 
responses in several ways (6).  This latter activity may be 
most important to interferon’s effectiveness in inducing 
viral clearance because agents that simply inhibit viral 
replication are rarely effective (7). 
If immunity is of benefit in resolving acute hepatitis B 
infection, how might it be deleterious in patients with 
chronic hepatitis B infection? A scenario can be envi- 
sioned where ongoing viral replication exists that for 
some reason cannot be controlled or eliminated. Cellular 
immune reactions continue to destroy infected cells; 
however, because the virus is not eliminated, this leads 
to progressive hepatic destruction. Such a scenario 
would require a paradoxical immune response: effective 
cytotoxic activity that can lyse infected hepatocytes, but 
the overall immune response that is, for some reason, 
unable to clear the infection. Although virulence char- 
acteristics of a particular strain of hepatitis B could be 
